Stock Financial Ratios, Dividends, Split History

CDR / Cedar Realty Trust, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)362.08
Enterprise Value ($M)940.28
Book Value ($M)560.56
Book Value / Share6.11
Price / Book0.58
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 91,899,221
Common Stock Shares Outstanding 91,317,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.02
Return on Equity (ROE)0.03
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Other Real Estate Revenue1,512,000.00
Operating Income42.06
Net Income19.65
Earnings Per Share Basic And Diluted-0.04
Cash Flow Statement (mra) ($M)
Cash From Operations57.53
Cash from Investing-46.44
Cash from Financing57.53
Identifiers and Descriptors
Central Index Key (CIK)761648

Split History

Stock splits are used by Cedar Realty Trust, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Cedar Realty Trust's (CDR) CEO Bruce Schanzer on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Cedar Realty Trust, Inc. (NYSE:CDR) Q1 2018 Earnings Conference Call May 1, 2018 5:00 AM ET (2-0)

With Activist Campaign Settled, Sexual Harassment Lawsuit Against Cedar Realty Trust Continues - ValueWalk

2018-04-19 valuewalk
As the “Me Too” movement was getting off the ground this past fall, an activist hedge fund campaign was underway to oust the president of Cedar Realty Trust (NYSE:CDR) a Port Washington, NY-based Real Estate Investment Trust that owns and operates nearly $670 million in primarily shopping malls located in the Washington DC to Boston beltway. While the dispute with the activist hedge fund, Snow Park Capital Partners, has been settled, what remains is a sexual harassment lawsuit that is approaching a pivotal moment in court. (2-0)

Cedar Realty Trust Chief Faces Sexual-Harassment Allegations - WSJ

2018-04-17 wsj
A Brooklyn judge will decide whether to allow a sexual-harassment and pay-discrimination lawsuit filed by former Cedar Realty Trust Inc. Chief Operating Officer Nancy Mozzachio against CEO Bruce Schanzer to proceed. (2-0)

Portfolio Review: Dividend Yields On Cost

2018-03-20 seekingalpha
Yield on cost is a great metric to measure how well a dividend growth stock is performing. (7-0)

CUSIP: 150602209